

ANSWERING REVIEWERS



September 2, 2014

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 11010-Review.doc).

Title: Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer

Authors: Vassilis Kouloulias, Anna Zygogianni, Efrosini Kypraiou, John Georgakopoulos, Zoi Thrapsanioti, Ivelina Beli, Eftychia Mosa, Amanta Psyrris, Christos Antypas, Christina Armbilia, Maria Tolia, Kalliopi Platoni, Christos Papadimitriou, Nikolaos Arkadopoulos, Costas Gennatas, George Zografos, George Kyrgias, Maria Dilvoi, George Patatoucas, Nikolaos Kelekis, John Kouvaris

Name of Journal: *World Journal of Clinical Cases*

ESPS Manuscript NO: 11010

The manuscript has been improved according to the suggestions of the reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer:

(1) 2445925

We thank the reviewer for his kind comments.

(2) 289470

- The authors should mention whether any treatment interruption due to toxicity has occurred.

Answer: No treatment interruption was occurred since no skin toxicity more than grade 3 was noted. (see revised text with characters in red)

- In the planned treatment, two variables have been changed at once: 1) dose per fraction 2) treatment time. Actually the RT schedule is hypofractionated accelerated, being delivered in a shorter time. Such acceleration might have impact acute reactions due to the weekly dose accumulation. The authors should account for this.

Answer: According to radiobiology and definitely according to the Whalen study, no increase of skin toxicity is noted during hypofractionation of 266cGy per fraction.

- The authors reported the maximum toxicity grade which have been experienced. It could be helpful to exclude (or not) any role or responsibility of the boost as concerns the occurrence of the acute skin reactions

Answer: We agree with the reviewer. Indeed the maximum grade of skin toxicity was noted during the whole breast irradiation and not during the boost radiotherapy. This comment has been included in the revised manuscript. (see revised text with characters in red).

Editors' comments:

- We have added fax and tel. numbers
- The citations of the references are now in superscript
- We have included the citation of 18 and 28 references
- We have added the summary(core tip)
- We have added also the comments such as background, research frontiers, innovations and breakthroughs, applications and terminology. (see revised text)

3 References and typesetting were corrected (DOI and PMID, where available from the Journals)

Thank you again for your fruitful comments concerning our manuscript.

Yours truly

A handwritten signature in black ink, appearing to be 'V. Kouloulis', written in a cursive style.

Dr. V. Kouloulis (MS,MD,PhD)

As. Professor Radiation Oncology

Medical School of Athens, Greece

Scientific director of the Radiotherapy Unit of ATTIKON University Hospital

Rimini 1, 12462, Xaidari

Athens, Greece